On June 30, 2021, upon the recommendation of the corporate governance and nominating committee of the Board of Directors of Trillium Therapeutics Inc., the Board appointed Catherine Mackey as a member of the Board, effective June 30, 2021. Dr. Mackey will serve as a director until the Company’s 2022 Annual General Meeting of Shareholders and thereafter until her successor has been duly elected and qualified or until a successor has been duly elected or appointed. Dr. Mackey has more than 30 years of operating experience in the pharmaceutical and biotechnology sectors. Dr. Mackey served as a member of the board of directors of Poseida Therapeutics, a publicly held clinical stage oncology company focused on gene engineering technologies, from January 2019 to June 2021. Since July 2019, Dr. Mackey has served as a member of the board of directors of AVID Bioservices, a publicly held contract development and manufacturing organization. From December 2017 to May 2021, Dr. Mackey served as a member of the board of directors of GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), a publicly held British biopharmaceutical company focused on the development of prescription cannabinoid-based medicines.